OncImmune was founded in 2003 to commercialise technology developed in the laboratories of Professor John Robertson, a professor of surgery at the University of Nottingham, England. Research continues in the laboratory of Professor Roberston, while development of products is funded through OncImmune, Ltd.

The first products the company plans to develop will be used as aids for the early detection of breast and ovarian cancer. The company plans to follow these products with aids to the early detection and characterisation of all the major solid tumour cancers.

In December of 2005, the company secured a substantial round of private investment, ensuring its ability to develop, and if scientifically justified, market the initially targeted products. In 2007 Oncimmune(USA)LLC was formed with Dr Anthony C Barnes as the Chief Executive Officer.